# GLP-1 drugs: therapeutic and economic impacts

> Live situation record from CLSTR: https://clstr.news/situations/glp-1-drugs-therapeutic-and-economic-impacts
> Updated: 2026-07-31T20:38:59.000Z. Sources: 16. Developments: 2.

Researchers are exploring GLP‑1 medications such as Ozempic, Wegovy and Zepbound for their potential to slow biological aging, noting that these drugs affect several hallmarks of aging and could become the first approved gerotherapeutics. While the FDA has not yet classified aging as a disease, scientists are using GLP‑1 agents off‑label and funding further studies.

A separate analysis of Danish health and employment records found that users of GLP‑1 drugs experienced a 17 % reduction in long‑term sick‑leave episodes compared with non‑users. The study linked this drop to the cardiovascular benefits of the drugs and estimated an economic saving of roughly US $866 per employee, suggesting broader payroll and policy implications that could extend to other countries such as the United States.

## Claims

- Patients on GLP-1 medications had 17.3 % fewer long-term sick‑leave episodes (>30 days) than comparable persons. (corroborated by 11 sources)
- Long-term sick leave was defined as absences longer than 30 days. (corroborated by 11 sources)
- The study estimated an economic benefit of 1.3 %–1.5 % of a worker’s annual income per employee using GLP-1 drugs. (corroborated by 11 sources)
- Average savings were estimated at about US $866 per employee for employers and health‑care systems. (corroborated by 11 sources)
- GLP-1 medications reduce the risk of cardiovascular events such as heart attack and stroke. (corroborated by 11 sources)
- The analysis used comprehensive Danish health and employment registers. (corroborated by 11 sources)
- Jonathan Zhang of Duke University is a co‑author of the study. (corroborated by 11 sources)
- Similar benefits could apply in the United States, where presentism is common. (corroborated by 11 sources)

## Timeline

### 2026-07-31: GLP-1 drugs Ozempic and Wegovy cut employee sick leave by 17%

Duke and NBER study shows GLP‑1 drugs Ozempic and Wegovy cut long‑term sick leave by 17 % and could save about $866 per worker, driven by reduced cardiovascular risk.

16 sources. https://clstr.news/cluster/glp1-therapies-improve-blood-sugar-and-reduce-fat-in-new-studies

### 2026-07-21: GLP-1 drugs considered promising candidates for longevity therapy

GLP‑1 drugs like Ozempic may affect aging biology and are being studied as potential longevity treatments, though no FDA‑approved anti‑aging medication exists yet.

5 sources. https://clstr.news/cluster/glp-1-drugs-considered-promising-candidates-for-longevity-therapy

---
Cite as: GLP-1 drugs: therapeutic and economic impacts. CLSTR, https://clstr.news/situations/glp-1-drugs-therapeutic-and-economic-impacts